CORONA Remedies Limited reported its audited standalone and consolidated financial results for the fourth quarter and full year ended March 31, 2026. The Board of Directors, at its meeting held on May 11, 2026, considered and approved the results. The company delivered robust performance across revenue and profitability metrics, driven by brand-building initiatives and operational efficiencies. The Board recommended a final dividend of ₹10 per equity share for FY26, with the record date fixed as Friday, June 19, 2026. Additionally, the Board approved the appointment of M/s. Walker Chandio & Co LLP as the Statutory Auditor for a period of five years.

Standalone Financial Performance

On a standalone basis, CORONA Remedies posted strong growth for FY26. Revenue from operations grew 17.3% year-on-year to ₹1,403.18 Crores from ₹1,196.42 Crores in FY25. Net profit after tax for FY26 was ₹184.85 Crores, up from ₹149.05 Crores in FY25. The company reported an exceptional item of ₹19.10 Crores (post-tax ₹14.29 Crores) in FY26, representing the statutory impact of the new Labour Codes notified by the Government of India. The table below summarises the standalone financial performance across Q4 FY26 and the full year:

Consolidated Financial Performance

On a consolidated basis, the company reported revenue from operations of ₹1,403.2 Crores for FY26 and a reported net profit after tax of ₹185.1 Crores. Adjusted for the one-time statutory impact of new Labour Codes of ₹19.1 Crores (post-tax ₹14.3 Crores), the adjusted PAT stood at ₹199.4 Crores, reflecting a 33.4% year-on-year growth. Consolidated total income for FY26 stood at ₹1,413.83 Crores versus ₹1,202.35 Crores in FY25. The consolidated financial highlights are presented below:

Key Highlights

The Board recommended a final dividend of ₹10/- per equity share for FY26. The record date is fixed as Friday, June 19, 2026. The company highlighted strategic milestones, including the acquisition of WOKADINE and 7 brands from Bayer Zydus Pharma. It received EAEU-GMP certification, enabling entry into markets including Russia and Kazakhstan. CORONA Remedies improved its industry ranking to 27th in India from 32nd.

Corona Remedies Limited has filed its quarterly regulatory certificate with stock exchanges for the fourth quarter ended March 31, 2026. The pharmaceutical company submitted the mandatory documentation to both BSE Limited and National Stock Exchange of India Limited on April 07, 2026, as part of its ongoing compliance obligations.

Regulatory Certificate Details

The certificate was filed pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. Company Secretary and Compliance Officer Chetna Dharajiya signed the submission letter, which was accompanied by the required certificate from the company's registrar.

Certificate Confirmation

Bigshare Services Private Limited, serving as the company's Registrar to Issue and Share Transfer Agent, issued the certificate dated March 31, 2026. The registrar confirmed that Regulation 74(5) is not applicable to Corona Remedies Limited during the specified quarter.

The key findings include:

• All company shares remain in demat form
• No requests received for rematerialisation during the quarter
• No requests received for dematerialisation during the quarter
• Full compliance with depositories regulations maintained

Compliance Framework

The filing demonstrates Corona Remedies' adherence to SEBI's regulatory framework for listed companies. The certificate was simultaneously submitted to both National Securities Depository Limited and Central Depository Services (India) Limited, ensuring comprehensive regulatory coverage.

Company Information

Corona Remedies Limited, formerly known as Corona Remedies Private Limited, operates from its registered office at Corona House in Ahmedabad, Gujarat. The company maintains its listing on both major Indian stock exchanges and continues to fulfill all mandatory disclosure requirements under securities regulations.